Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Clinical trial NCT03517449 · COMPLETED
Trial details
- NCT number
- NCT03517449
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-11
- Primary completion
- 2022-03-01
- Enrollment
- 827
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.